2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2024

Replacing Radiographic Sacroiliitis By Structural Lesions on MRI of the Sacroiliac Joints in Two Early Axial Spa Cohorts: What Is the Impact on the Classification of Patients According to the ASAS Axial Spa Criteria?
Abstract Number: 2025

Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Abstract Number: 2026

A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2027

Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Abstract Number: 2028

Contribution of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia Rheumatica: A Controlled Study
Abstract Number: 2029

Fever of Unknown Origin (FUO) and Inflammation of Unknown Origin (IUO): Is 18f-FDG-PET/CT a Useful First Line Diagnostic Strategy?
Abstract Number: 2030

MRI Changes Associated with Neurological Compromise in Acute Pyogenic Vertebral Osteomyelitis: A Retrospective Study of 121 Patients
Abstract Number: 2031

Tuberculosis in Patients Treated with Biological Drugs
Abstract Number: 2032

Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Abstract Number: 2033

Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection
Abstract Number: 2034

Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Abstract Number: 2035

Clinical Characteristics and Outcomes of Polyarticular Septic Arthritis
Abstract Number: 2036

Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network
Abstract Number: 2037

Rheumatic Manifestations May be the First Clinical Presentation of Arterial Calcification Due to CD73 Deficiency
Abstract Number: 2038

Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].